BR112022011349A2 - Células para tratar câncer - Google Patents
Células para tratar câncerInfo
- Publication number
- BR112022011349A2 BR112022011349A2 BR112022011349A BR112022011349A BR112022011349A2 BR 112022011349 A2 BR112022011349 A2 BR 112022011349A2 BR 112022011349 A BR112022011349 A BR 112022011349A BR 112022011349 A BR112022011349 A BR 112022011349A BR 112022011349 A2 BR112022011349 A2 BR 112022011349A2
- Authority
- BR
- Brazil
- Prior art keywords
- treat cancer
- cells
- granulocytes
- relates
- granulocyte
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- 210000003714 granulocyte Anatomy 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/54—Pancreas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1918313.6A GB201918313D0 (en) | 2019-12-12 | 2019-12-12 | Cells for treating cancer |
| PCT/GB2020/053199 WO2021116713A1 (en) | 2019-12-12 | 2020-12-11 | Cells for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022011349A2 true BR112022011349A2 (pt) | 2022-08-23 |
Family
ID=69186690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022011349A BR112022011349A2 (pt) | 2019-12-12 | 2020-12-11 | Células para tratar câncer |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230203441A1 (enExample) |
| EP (1) | EP4073509A1 (enExample) |
| JP (1) | JP2023509849A (enExample) |
| CN (1) | CN115136005A (enExample) |
| AU (1) | AU2020402167A1 (enExample) |
| BR (1) | BR112022011349A2 (enExample) |
| CA (1) | CA3173535A1 (enExample) |
| GB (1) | GB201918313D0 (enExample) |
| IL (1) | IL293740A (enExample) |
| WO (1) | WO2021116713A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201618106D0 (en) | 2016-10-26 | 2016-12-07 | Lift Biosciences Ltd | Cancer-killing cells |
| WO2024189333A1 (en) | 2023-03-10 | 2024-09-19 | Lift Biosciences Ltd | Immunomodulatory cells and compositions |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| US9199028B2 (en) * | 2010-01-15 | 2015-12-01 | Memorial Sloan-Kettering Cancer Center | Use of entrained neutrophils to treat metastatic and micrometastatic disease in at risk patients |
| WO2016020530A1 (en) * | 2014-08-07 | 2016-02-11 | Reponex Pharmaceuticals Aps | Compositions for the treatment of periotonitis |
-
2019
- 2019-12-12 GB GBGB1918313.6A patent/GB201918313D0/en not_active Ceased
-
2020
- 2020-12-11 CN CN202080096399.1A patent/CN115136005A/zh active Pending
- 2020-12-11 JP JP2022535595A patent/JP2023509849A/ja active Pending
- 2020-12-11 AU AU2020402167A patent/AU2020402167A1/en active Pending
- 2020-12-11 WO PCT/GB2020/053199 patent/WO2021116713A1/en not_active Ceased
- 2020-12-11 EP EP20839137.5A patent/EP4073509A1/en active Pending
- 2020-12-11 US US17/785,012 patent/US20230203441A1/en active Pending
- 2020-12-11 BR BR112022011349A patent/BR112022011349A2/pt unknown
- 2020-12-11 IL IL293740A patent/IL293740A/en unknown
- 2020-12-11 CA CA3173535A patent/CA3173535A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3173535A1 (en) | 2021-06-17 |
| IL293740A (en) | 2022-08-01 |
| EP4073509A1 (en) | 2022-10-19 |
| US20230203441A1 (en) | 2023-06-29 |
| GB201918313D0 (en) | 2020-01-29 |
| CN115136005A (zh) | 2022-09-30 |
| JP2023509849A (ja) | 2023-03-10 |
| AU2020402167A1 (en) | 2022-06-09 |
| WO2021116713A1 (en) | 2021-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022009723A2 (pt) | Anticorpos específicos para cd47, pd-l1, e usos dos mesmos | |
| BR112018071276A2 (pt) | anticorpos anti-il-33, composições, métodos e usos dos mesmos | |
| EA201592074A1 (ru) | Композиции и способы изменения сигнальной системы вторичного мессенджера | |
| EP4368992A3 (en) | Simultaneous quantification of a plurality of proteins in a user-defined region of a cross-sectioned tissue | |
| EP4368728A3 (en) | Simultaneous quantification of gene expression in a user-defined region of a cross-sectioned tissue | |
| EA201792542A1 (ru) | Способ и конструкции специфического редактирования нуклеиновой кислоты у растений | |
| BR112018067408A2 (pt) | formas sólidas de um inibidor de acc de tienopirimidinadiona e métodos para a produção das mesmas | |
| BR112019018685A8 (pt) | Anticorpos, composição farmacêutica, kit, usos de um anticorpo e método in vitro de identificação ou seleção de um anticorpo | |
| BR112015006060A2 (pt) | agentes de ligação kir3dl2 | |
| MX2017010746A (es) | Composicion y metodos para la expresion regulada de un complejo de arn guia/endonucleasa cas. | |
| EA201791633A1 (ru) | Способ точной модификации растения посредством транзиентной экспрессии гена | |
| BR112017027498A2 (pt) | anticorpo, ácido nucleico, composto, composição, e, método para tratamento de um paciente com uma doença. | |
| BR112015022602A2 (pt) | composições compreendendo compostos de tienopirimidina e tienopiridina e métodos de uso dos mesmos | |
| BR112018077362A2 (pt) | conjugados para edição de superfície de célula-alvo | |
| MX2015013202A (es) | Cultivo, produccion, procesamiento y uso de cannabis de especialidad. | |
| MX384138B (es) | Anticuerpos anti-c5 y métodos para su uso. | |
| EA201490533A1 (ru) | Способы и композиции для определения статуса в отношении курения | |
| BR112015014751A2 (pt) | anticorpos anti-tau humanos | |
| MX387719B (es) | Biomarcadores de la enfermedad del hígado graso no alcohólico (nafld) y la esteatohepatitis no alcohólica (nash) y usos de estos. | |
| ECSP11010805A (es) | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 | |
| BR112015023262A2 (pt) | anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo | |
| BR112013008480A2 (pt) | anticorpos contra tumor e usos específicos dos mesmos | |
| CO6430501A2 (es) | Nuevos compuestos eficaces como inhibidores de la xantina-oxidasa, método para la preparación de los mismos y composición farmacéutica que los contiene | |
| MX389703B (es) | Anticuerpos anti-c1s humanizados y metodos para usarlos. | |
| AR093446A1 (es) | Anticuerpos de antihemaglutinina y metodos de uso |